{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.73","upperLimit":"11.5","value":"7.29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Total apparent body clearance of drug from the plasma after oral administration (volume x time-1).","dispersionType":"Full Range","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"}],"paramType":"MEDIAN","populationDescription":"Participants in the Pharmacokinetic analysis set (PAS) with an available value for the outcome measure. PAS included all participants who provided at least one evaluable PK concentration of asciminib.","reportingStatus":"POSTED","timeFrame":"Week 2 day 1 at: 0hr (pre-dose), 0.5hr, 1hr, 2hr, 3hr, 4hr, 6hr, 8hr & 12hr post-dose","title":"PK Parameter: CL/F for Asciminib","type":"SECONDARY","unitOfMeasure":"L/hr"}